{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T08:59:30Z","timestamp":1785142770815,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100005046","name":"Natural Science Foundation of Heilongjiang Province","doi-asserted-by":"publisher","award":["LH2023H032"],"award-info":[{"award-number":["LH2023H032"]}],"id":[{"id":"10.13039\/501100005046","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Scientific Research Project of Wu Jieping Medical Foundation","award":["320.6750.2024-18-37"],"award-info":[{"award-number":["320.6750.2024-18-37"]}]},{"name":"fundamental research funds for China Postdoctoral Science Foundation","award":["2025M781968"],"award-info":[{"award-number":["2025M781968"]}]},{"name":"provincial universities in heilongjiang province","award":["2025-KYYWF-ZR0230"],"award-info":[{"award-number":["2025-KYYWF-ZR0230"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82274028"],"award-info":[{"award-number":["82274028"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005046","name":"Key Project of Natural Science Foundation of Heilongjiang Province","doi-asserted-by":"crossref","award":["ZL2024H005"],"award-info":[{"award-number":["ZL2024H005"]}],"id":[{"id":"10.13039\/501100005046","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Toxicol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s12012-026-10141-8","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T02:25:30Z","timestamp":1783477530000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Arsenic Plasma Concentrations and Methylation Efficiency as Key Factors of Arsenic Trioxide-Related Cardiac Toxicity in Acute Promyelocytic Leukemia"],"prefix":"10.1007","volume":"26","author":[{"given":"Meihua","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenli","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoting","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhibo","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi\u2019ao","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zengliang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Al-Mhmody","family":"Husam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Hai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"issue":"7","key":"10141_CR1","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.3324\/haematol.2021.280093","volume":"107","author":"A \u00d6sterroos","year":"2022","unstructured":"\u00d6sterroos, A., Maia, T., Eriksson, A., J\u00e4dersten, M., Lazarevic, V., Wennstr\u00f6m, L., et al. (2022). A risk score based on real-world data to predict early death in acute promyelocytic leukemia. Haematologica, 107(7), 1528\u20131537.","journal-title":"Haematologica"},{"issue":"2","key":"10141_CR2","first-page":"58","volume":"5","author":"M Aznab","year":"2015","unstructured":"Aznab, M., & Rezaei, M. (2015). Induction, consolidation, and maintenance therapies with arsenic as a single agent for acute promyelocytic leukaemia in a 11-year follow-up. Hematological Oncology, 5(2), 58\u201367.","journal-title":"Hematological Oncology"},{"key":"10141_CR3","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1038\/leu.2017.92","volume":"31","author":"S Kayser","year":"2017","unstructured":"Kayser, S., Krzykalla, J., Elliott, M. A., Norsworthy, K., Gonzales, P., Hills, R. K., et al. (2017). Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide. Leukemia, 31, 2347\u20132354.","journal-title":"Leukemia"},{"issue":"2","key":"10141_CR4","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s12012-018-09504-7","volume":"19","author":"VP Vineetha","year":"2019","unstructured":"Vineetha, V. P., & Raghu, K. G. (2019). An overview on arsenic trioxide-induced cardiotoxicity. Cardiovascular Toxicology, 19(2), 105\u2013119.","journal-title":"Cardiovascular Toxicology"},{"issue":"33","key":"10141_CR5","doi-asserted-by":"publisher","first-page":"3723","DOI":"10.1200\/JCO.2013.51.2913","volume":"32","author":"GJ Roboz","year":"2014","unstructured":"Roboz, G. J., Ritchie, E. K., Carlin, R. F., Samuel, M., Samuel, M., Gale, L., et al. (2014). Prevalence, management, and clinical consequences of QT interval prolongation during treatment with arsenic trioxide. Journal of Clinical Oncology, 32(33), 3723\u20133728.","journal-title":"Journal of Clinical Oncology"},{"issue":"24","key":"10141_CR6","doi-asserted-by":"publisher","first-page":"3866","DOI":"10.1200\/JCO.2010.28.5031","volume":"28","author":"V Mathews","year":"2010","unstructured":"Mathews, V., George, B., Chendamarai, E., Lakshmi, K. M., Desire, S., Balasubramanian, P., et al. (2010). Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: Long-term follow-up data. Journal of Clinical Oncology, 28(24), 3866\u20133871.","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10141_CR7","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.3324\/haematol.2021.278722","volume":"106","author":"S Kayser","year":"2021","unstructured":"Kayser, S., Schlenk, R. F., Lebon, D., Carre, M., St\u00f6lzel, F., Berceanu, A., et al. (2021). Characteristics and outcome of patients with low-\/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: An international collaborative study. Haematologica, 106(12), 3100\u20133106.","journal-title":"Haematologica"},{"issue":"22","key":"10141_CR8","doi-asserted-by":"publisher","first-page":"4034","DOI":"10.1182\/blood.V128.22.4034.4034","volume":"128","author":"MS Tallman","year":"2016","unstructured":"Tallman, M. S., Lo-Coco, F., & Pathak, A. (2016). Long-term safety experience with arsenic trioxide in patients with acute promyelocytic leukemia. Blood, 128(22), 4034.","journal-title":"Blood"},{"key":"10141_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00619-3","volume":"12","author":"UP Kulkarni","year":"2022","unstructured":"Kulkarni, U. P., Selvarajan, S., Lionel, S., Prakash, M. A., Palani, H. K., Balasundaram, N., et al. (2022). Real world data with concurrent retinoic acid and arsenic trioxide for the treatment of acute promyelocytic leukemia. Blood Cancer Journal, 12, Article 22.","journal-title":"Blood Cancer Journal"},{"key":"10141_CR10","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1080\/17512433.2021.1893940","volume":"14","author":"M Guo","year":"2021","unstructured":"Guo, M., Zhou, J., Fan, S., Li, L., Chen, H., Lin, L., et al. (2021). Characteristics and clinical influence factors of arsenic species in plasma and their role of arsenic species as predictors for clinical efficacy in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide. Expert Review of Clinical Pharmacology, 14, 503\u2013512.","journal-title":"Expert Review of Clinical Pharmacology"},{"key":"10141_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.887026","volume":"12","author":"M Guo","year":"2022","unstructured":"Guo, M., Lv, J., Chen, X., Wu, M., Zhao, Q., & Hai, X. (2022). Arsenic trioxide therapy during pregnancy: ATO and its metabolites in maternal blood and amniotic fluid of acute promyelocytic leukemia (APL) patients. Frontiers in Oncology, 12, Article 887026.","journal-title":"Frontiers in Oncology"},{"issue":"1","key":"10141_CR12","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/toxsci\/kfy210","volume":"166","author":"J Lu","year":"2018","unstructured":"Lu, J., Hu, S., Wang, W., Li, J., Dong, Z., Zhou, J., et al. (2018). AS3MT polymorphisms, arsenic metabolism, and the hematological and biochemical values in APL patients treated with arsenic trioxide. Toxicological Sciences, 166(1), 219\u2013227.","journal-title":"Toxicological Sciences"},{"issue":"4","key":"10141_CR13","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1080\/17512433.2019.1586532","volume":"12","author":"M Guo","year":"2019","unstructured":"Guo, M., Wang, B., Liu, S., Wang, W., Gao, C., Hu, S., et al. (2019). Time course of arsenic species in red blood cells of acute promyelocytic leukemia (APL) patients treated with single agent arsenic trioxide. Expert Review of Clinical Pharmacology, 12(4), 371\u2013378.","journal-title":"Expert Review of Clinical Pharmacology"},{"key":"10141_CR14","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jes.2016.10.004","volume":"49","author":"B Moe","year":"2016","unstructured":"Moe, B., Peng, H., Lu, X., Chen, B., Chen, L. W. L., Gabos, S., et al. (2016). Comparative cytotoxicity of fourteen trivalent and pentavalent arsenic species determined using real-time cell sensing. Journal of Environmental Sciences (China), 49, 113\u2013124.","journal-title":"Journal of Environmental Sciences (China)"},{"issue":"9","key":"10141_CR15","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1080\/17512433.2021.1938549","volume":"14","author":"Q Zhao","year":"2021","unstructured":"Zhao, Q., Guo, M., Hostetter, T. H., Chen, H., Lin, L., & Hai, X. (2021). Effect of renal impairment on arsenic accumulation, methylation capacity, and safety in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide. Expert Review of Clinical Pharmacology, 14(9), 1173\u20131182.","journal-title":"Expert Review of Clinical Pharmacology"},{"key":"10141_CR16","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.3390\/foods14132229","volume":"14","author":"P Visciano","year":"2025","unstructured":"Visciano, P. (2025). Arsenic in water and food: Toxicity and human exposure. Foods, 14, 2229.","journal-title":"Foods"},{"issue":"23","key":"10141_CR17","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1001\/jama.2025.19161","volume":"334","author":"F Wu","year":"2025","unstructured":"Wu, F., van Geen, A., Graziano, J., Ahmed, K. M., Liu, M., Argos, M., et al. (2025). Arsenic exposure reduction and chronic disease mortality. Journal Of The American Medical Association, 334(23), 2104\u20132112.","journal-title":"Journal of the American Medical Association"},{"key":"10141_CR18","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.jpba.2017.07.001","volume":"145","author":"M Guo","year":"2017","unstructured":"Guo, M., Wang, W., Hai, X., & Zhou, J. (2017). HPLC-HG-AFS determination of arsenic species in acute promyelocytic leukemia (APL) plasma and blood cells. Journal of Pharmaceutical and Biomedical Analysis, 145, 356\u2013363.","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10141_CR19","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1080\/17512433.2024.2417666","volume":"17","author":"C Gao","year":"2024","unstructured":"Gao, C., Duan, R., Tian, S., Pang, C., Zhang, H., Yang, H., et al. (2024). Plasma protein binding of arsenic species in acute promyelocytic leukemia patients and their relationships with hepatic and renal function. Expert Review of Clinical Pharmacology, 17, 1063\u20131069.","journal-title":"Expert Review of Clinical Pharmacology"},{"key":"10141_CR20","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.toxlet.2021.04.005","volume":"347","author":"S Guo","year":"2021","unstructured":"Guo, S., Wang, X., Gao, C., Wu, Z., Chen, H., Lin, L., et al. (2021). Monomethylated arsenic was the major methylated arsenic in red blood cells of acute promyelocytic leukemia patients treated with arsenic trioxide. Toxicology Letters, 347, 78\u201385.","journal-title":"Toxicology Letters"},{"issue":"14","key":"10141_CR21","doi-asserted-by":"publisher","first-page":"23905","DOI":"10.18632\/oncotarget.14733","volume":"8","author":"I Khairul","year":"2017","unstructured":"Khairul, I., Wang, Q. Q., Jiang, Y. H., Wang, C., & Naranmandura, H. (2017). Metabolism, toxicity and anticancer activities of arsenic compounds. Oncotarget, 8(14), 23905\u201323926.","journal-title":"Oncotarget"},{"key":"10141_CR22","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1146\/annurev-pharmtox-051921-020936","volume":"63","author":"MA El-Ghiaty","year":"2023","unstructured":"El-Ghiaty, M. A., & El-Kadi, A. O. S. (2023). The duality of arsenic metabolism: Impact on human health. Annual Review of Pharmacology and Toxicology, 63, 341\u2013358.","journal-title":"Annual Review of Pharmacology and Toxicology"},{"issue":"6","key":"10141_CR23","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1021\/tx400123q","volume":"26","author":"B Chen","year":"2013","unstructured":"Chen, B., Lu, X., Shen, S., Arnold, L. L., Cohen, S. M., & Le, X. C. (2013). Arsenic speciation in the blood of arsenite-treated F344 rats. Chemical Research in Toxicology, 26(6), 952\u2013962.","journal-title":"Chemical Research in Toxicology"},{"key":"10141_CR24","doi-asserted-by":"publisher","first-page":"114201","DOI":"10.1016\/j.jpba.2021.114201","volume":"203","author":"X Wang","year":"2021","unstructured":"Wang, X., Qian, Z., Li, H., Chen, H., Lin, L., Guo, M., et al. (2021). Evaluation of arsenic species in leukocytes and granulocytes of acute promyelocytic leukemia patients treated with arsenic trioxide. Journal of Pharmaceutical and Biomedical Analysis, 203, 114201.","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10141_CR25","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jpba.2019.04.014","volume":"171","author":"M Guo","year":"2019","unstructured":"Guo, M., Li, J., Fan, S., Liu, W., Wang, B., Gao, C., et al. (2019). Speciation analysis of arsenic in urine samples from APL patients treated with single agent As2O3 by HPLC-HG-AFS. Journal of Pharmaceutical and Biomedical Analysis, 171, 212\u2013217.","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10141_CR26","doi-asserted-by":"publisher","first-page":"18583","DOI":"10.1074\/jbc.R900003200","volume":"284","author":"LC Platanias","year":"2009","unstructured":"Platanias, L. C. (2009). Biological responses to arsenic compounds. Journal of Biological Chemistry, 284, 18583\u201318587.","journal-title":"Journal of Biological Chemistry"},{"key":"10141_CR27","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.envpol.2018.04.129","volume":"240","author":"KA Moon","year":"2018","unstructured":"Moon, K. A., Zhang, Y., Guallar, E., Francesconi, K. A., Goessler, W., Umans, J. G., et al. (2018). Association of low-moderate urine arsenic and QT interval: Cross-sectional and longitudinal evidence from the Strong Heart Study. Environmental Pollution, 240, 894\u2013902.","journal-title":"Environmental Pollution"},{"key":"10141_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2019.114687","volume":"379","author":"J Lu","year":"2019","unstructured":"Lu, J., Yu, K., Fan, S., Liu, W., Dong, Z., Li, J., et al. (2019). Influence of AS3MT polymorphisms on arsenic metabolism and liver injury in APL patients treated with arsenic trioxide. Toxicology and Applied Pharmacology, 379, Article 114687.","journal-title":"Toxicology and Applied Pharmacology"},{"key":"10141_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.etap.2023.104142","volume":"100","author":"M Wu","year":"2023","unstructured":"Wu, M., Pang, C., Lu, S., Hostetter, T. H., & Hai, X. (2023). Type 2 diabetes affects arsenic metabolism via transporters in arsenic trioxide treated acute promyelocytic leukemia patients. Environmental Toxicology and Pharmacology, 100, Article 104142.","journal-title":"Environmental Toxicology and Pharmacology"}],"container-title":["Cardiovascular Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-026-10141-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12012-026-10141-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-026-10141-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T08:02:01Z","timestamp":1785139321000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12012-026-10141-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10141"],"URL":"https:\/\/doi.org\/10.1007\/s12012-026-10141-8","relation":{},"ISSN":["1530-7905","1559-0259"],"issn-type":[{"value":"1530-7905","type":"print"},{"value":"1559-0259","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"3 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"73"}}